title: Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin.
abstract: The first generation protease inhibitors has been the mainstay of hepatitis C treatment for the last couple of years, showing marked improvement in sustained virological response, but also increased side effects. Infection has emerged as a common complication of telaprevir and boceprevir in combination with peginterferon and ribavirin, usually caused by common pathogens. We present the case of a 65 years old man who developed a Mycobacterium abscessus pulmonary infection during treatment with telaprevir, peginterferon and ribavirin. The patient was successfully treated with amikacin, imipenem and chlarithromycin. The present case is relevant for increasing awareness for recognition of opportunistic infections and particularly nontuberculous mycobacterial infections in patients receiving triple therapy for chronic hepatitis C, especially in cirrhotic subjects who develop significant lymphopenia.
authors.affiliation: Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Soza
authors.affiliation: Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Pilar
authors.initials: P
authors.lastname: Labbé
authors.affiliation: Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Marco
authors.initials: M
authors.lastname: Arrese
authors.affiliation: Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Riquelme
authors.affiliation: Afiliacja Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Francisco
authors.initials: F
authors.lastname: Barrera
authors.affiliation: Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Carlos
authors.initials: C
authors.lastname: Benítez
authors.affiliation: Department of Radiology, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Huete
authors.affiliation: Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: M Elvira
authors.initials: ME
authors.lastname: Balcells
authors.affiliation: Department of Infectious Diseases, School of Medicine, Pontificia Universidad Católica de Chile.
authors.forename: Jaime
authors.initials: J
authors.lastname: Labarca
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D016898:Interferon-alpha / Q000009:adverse effects*; D008231:Lymphopenia / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D009161:Mycobacterium; D009165:Mycobacterium Infections, Nontuberculous / Q000139:chemically induced* / Q000276:immunology; D009842:Oligopeptides / Q000009:adverse effects*; D018410:Pneumonia, Bacterial / Q000139:chemically induced* / Q000276:immunology; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a